A1: Sanofi Pasteur is participating in CIIE for our fourth consecutive year. Through our participation, we hope to quickly introduce innovative vaccines and disease prevention solutions to benefit the Chinese people. We also look forward to working with partners across sectors to empower local vaccine innovation and support the public health system, helping better combat emerging infectious diseases and safeguard public health. At this year's CIIE, we will also demonstrate our New Health Formula for vaccine innovation.

A2: Of course. The huge spillover effect we have seen in previous years' CIIEs has led to more engagement and partnerships in cutting-edge technologies, products and solutions, as well as cross-regional economic and trade collaboration. We can expect similar results this year to bolster economies and industries impacted by the COVID-19 pandemic. This year's CIIE also highlights how China is making every effort to not only power its own growth, but also contribute positively to the revival of the world economy.

A3: COVID-19 has had an immeasurable impact on the world economy. As the world's second-largest economy, China, with a population of 1.4 billion, has largely emerged from the pandemic. China's efforts to boost imports will undoubtedly be a key driver for the recovery and development of the world economy while continuing to play an important role in ensuring the stability and growth of the global economy.

A4: As the world's No 2 vaccine market, China is one of Sanofi Pasteur's key global markets. As Chinese people place increasing value on disease prevention while enjoying rising spending power and quality of life, they desire better-quality vaccines and health protection solutions. The pandemic has also starkly highlighted the importance of vaccines among both the government and the general public. These trends are further bolstering the entire vaccine industry, encouraging vaccine makers to develop innovative and high-quality vaccines to meet people's needs.

A5: In recent years, we've seen the government's determination to open up at a higher level, further encourage innovation and create a business-friendly environment. As the first multinational vaccine company to enter China and establish a world-leading local vaccine production site, Sanofi Pasteur has been encouraged and inspired by these efforts and is more confident about its business growth in China. We will continue to improve the availability of innovative vaccines and spare no effort to make new contributions to preventive health and immunization in China.

A6: Sanofi Pasteur remains firmly optimistic about China's market vitality and economic potential. We are encouraged by China's continued efforts to open up, develop a world-class business environment and support innovation-driven growth. We are currently moving ahead with several new initiatives in the Guangdong-Hong Kong-Macao Greater Bay Area, which is on the cutting edge of China's reform and opening-up. For example, we are delivering the China-French strategic partnership on vaccination, developing the nation's first strategic model for urban immunization planning and building China's first international vaccine innovation center.

A7: In the future, we hope China will continue to improve the priority review system for innovative vaccines, aligning with global practices in vaccine research and development, production and management. We also hope the government can provide comprehensive support in policy design and deployment for innovative technologies and products that can be used to respond to public health emergencies. We hope to work with the government to jointly improve the accessibility of innovative vaccines, so the Chinese people can have access to high-quality vaccines simultaneously with people in countries around the world.

A8: To address the challenges posed by the pandemic and the resulting economic recovery, China last year proposed a new development model in which domestic and international circulations complement each other. This model will give full play to China's ultra-large market and strong consumption power, contributing to the recovery and development of the world economy. The proposal of this dual circulation model clearly demonstrates China's willingness to leverage its economic strength to drive global economic revival.

Under the new dual circulation model, we will also give full play to our expertise as a global leader in vaccines, as we work with local innovative companies to meet the increasing health needs of the people.